Small Molecular TKI Target Treatment: Precision against Cancer

1. The introduction of the small molecular glycerine accelerator (TKI) is an important target-oriented therapeutic drug that inhibits the growth and growth of tumour cells by inhibiting the specific gyanase accelerator activity within tumour cells and by disrupting the transmission of signals. TKI has shown significant efficacy in a variety of cancer treatments, especially for non-small cell lung cancer (NSCLC) and breast cancer. 2. TKI ‘ s mechanism of action TKI prevents phosphoric acidification and activation of tumour cells mainly by inhibiting skin growth factor receptors (EGFR) in cells and the ATP position of Her2. They can disrupt the formation of the homogenous and heterogenic diaphragms of EgFR and Her2 and thus lower the signal transfer and kill cancer cells. In addition, TKI is able to show excellent efficacy in the treatment of HeR2 positive breast cancer brain transfer patients through the blood and brain barrier. TKI uses non-small cell lung cancer (NSCLC), the most common type of lung cancer, and TKI plays an important role in the treatment of NSCLC. The EGFR mutation NSCLC patients are sensitive to the EGFR-TKI treatment, while the ARK recast patients are very responsive to the ARK-TKI. The first generation of Alkal-Tkiktinib is a first-line treatment for the patients of the NSALC, but there are drug resistance problems. A new generation of TKIs, such as BBT-176 and CH7233163, are being studied with a view to overcoming drug resistance and improving treatment effectiveness. TKI’s application to breast cancer treatment is in the form of breast cancer treatment, where TKI, along with large molecules, ADC drugs, is known as the “three giants” of the breast cancer drug target. The main TKI drugs in the country’s clinical applications include Quicatini, Lapatini and Nailatini. By inhibiting the growth of her positive breast cancer cells, these drugs show good treatment and some efficacy in brain transfer therapy. 5. A major challenge for TKI ‘ s drug resistance and joint treatment of TKI treatment is the generation of resistance. Resistance may be caused by secondary resistance mutations and side-activation. In order to overcome drug resistance, researchers are exploring joint TKI treatment strategies with other drugs, such as the EGFR-TKI joint antivascular-generative drug, which could bring additional clinical benefits and delay the onset of resistance. The finalist TKI target provides a precision weapon for cancer treatment. TKI applications will become more individualized and precise as the tumour molecular mechanisms become better understood. Future research will continue to explore new targets for TKI, new drugs and new strategies to overcome drug resistance in order to improve the effectiveness of treatment and the quality of life of patients. This article combines information from multiple sources and provides you with a comprehensive TKI treatment perspective. I hope this will help you. If you have any other questions or need more detailed information, please be kept informed.